Study Finds New Genetic Variants in Ovarian Cancer

Article

A new international study has identified 12 new genetic variants associated with an increased risk of developing epithelial ovarian cancer.

A new international study has identified 12 new genetic variants associated with an increased risk of developing epithelial ovarian cancer (EOC).

Investigators report in Nature Genetics that they have identified nine new susceptibility loci for different epithelial ovarian cancer histotypes. Among these 9 loci, they have identified six for serous EOC histotypes (3q28, 4q32.3, 8q21.11, 10q24.33, 18q11.2, and 22q12.1), two for mucinous EOC (3q22.3 and 9q31.1), and one for endometrioid EOC (5q12.3). OBFC1, a new candidate susceptibility gene for low-grade and borderline serous EOC, was also identified.

Investigators at the Moffitt Cancer Center analyzed 25,509 EOC cases and 40,941 controls from pooled data from multiple genome-wide genotyping projects. They conducted a meta-analysis of 31,448 BRCA1 and BRCA2 mutation carriers (including 3,887 mutation carriers with EOC) to better understand the association between mutation carriers with EOC and BRCA2 mutation carriers. Using this approach, they found three additional susceptibility loci at 2q13, 8q24.1, and 12q24.31.

The new study is from the OncoArray Consortium, a collaborative effort that includes more than 400 scientists from the United States, United Kingdom, and Australia. Prior to this study, researchers had identified 27 common genetic variants, which account for roughly 4% of inherited risk for the disease.

The current investigation identifies 12 new genetic variants associated with ovarian cancer risk and it confirms 18 previously published variants. In total, there are 30 known generic variants associated with ovarian cancer risk, accounting for 6.5% of the inherited risk.

“We now need to take a closer look at the effect these variants have at the molecular and cellular levels.  If we can understand how they work, we can improve treatment options and work towards the prevention of ovarian cancer,” said Catherine Phelan, MD, PhD, MMS, who is an associate member of the Cancer Epidemiology Program at Moffitt Cancer Center, Tampa, Florida.

Phelan said this study highlights that fact that ovarian cancer is a very complex disease. She also notes that the 30 known risk variants account for just a small fraction of the inherited component and there will likely be many more genetic variants involved.

When a patient is diagnosed and treated in the early stages of ovarian, the 5-year survival rate is over 90%. However, only about 20% of all cases are caught early. It is hoped that it may be possible to pick up cases earlier through a better understanding of the genetic underpinnings of EOC.

Moffitt Cancer Center Director Thomas Sellers, PhD, MPH, said these latest findings are further proof that progress in the prevention and cure of cancer requires collaboration. This may be especially true for ovarian cancer. Sellers noted the current investigation involved pooling more than 60 independent studies from around the world.

 

 

Recent Videos
The Foundation for Women’s Cancer provides multicultural resources for patients with gynecologic cancers to help address gaps in care.
Ginger J. Gardner, MD, FACOG, addresses the growing uterine cancer cases among patients in the United States and the need for greater genetic testing.
Ginger J. Gardner, MD, FACOG, discussed the state of gynecologic cancers and her role in empowering research, education, and awareness surrounding them.
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Developing novel regimens may continue to improve survival outcomes of patients with advanced cervical cancer following the FDA approval of pembrolizumab and chemoradiation, says Jyoti S. Mayadev, MD.
Treatment with pembrolizumab plus chemoradiation appears to be well tolerated with no detriment to quality of life among those with advanced cervical cancer.
Jyoti S. Mayadev, MD, says that pembrolizumab in combination with chemoradiation will be seamlessly incorporated into her institution’s treatment of those with FIGO 2014 stage III to IVA cervical cancer following the regimen’s FDA approval.
Domenica Lorusso, MD, PhD, says that paying attention to the quality of chemoradiotherapy is imperative to feeling confident about the potential addition of pembrolizumab for locally advanced cervical cancer.
Related Content